Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $613.82 | $1,227.64 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,463 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $612.45 | $1,837.35 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,465 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 1, 2022 at prices ranging from $612.08 to $612.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $611.04 | $1,833.12 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,468 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 1, 2022 at prices ranging from $611.00 to $611.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $610.83 | $1,832.49 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,471 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 1, 2022 at prices ranging from $610.68 to $610.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $609.61 | $1,828.83 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,474 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 1, 2022 at prices ranging from $609.18 to $609.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $608.48 | $1,216.96 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,477 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on March 1, 2022 at prices ranging from $608.30 to $608.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $607.28 | $1,821.84 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,479 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 1, 2022 at prices ranging from $607.00 to $607.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $611.33 | $3,056.65 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,482 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on February 1, 2022 at prices ranging from $611.06 to $611.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $610.17 | $3,050.85 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,487 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on February 1, 2022 at prices ranging from $610.02 to $610.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 36 | $609.50 | $21,942.00 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,492 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 36 shares of Company stock on February 1, 2022 at prices ranging from $609.00 to $609.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $608.74 | $608.74 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,528 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $607.56 | $1,822.68 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,529 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on February 1, 2022 at prices ranging from $607.46 to $607.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20 | $606.74 | $12,134.80 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,532 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 20 shares of Company stock on February 1, 2022 at prices ranging from $606.07 to $606.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $605.50 | $4,238.50 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,552 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on February 1, 2022 at prices ranging from $605.19 to $605.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $604.26 | $604.26 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,559 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $603.61 | $3,621.66 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,560 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on February 1, 2022 at prices ranging from $603.06 to $603.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13 | $602.35 | $7,830.55 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,566 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 13 shares of Company stock on February 1, 2022 at prices ranging from $602.09 to $602.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2022 at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $601.79 | $601.79 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,579 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:16 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $600.89 | $1,201.78 |
DisclosureSEC source: 0001708138-22-000012 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,580 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · derivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 F10 · derivative.exercise_date: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,582 F9 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $628.87 | $1,257.74 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,391 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on January 3, 2022 at prices ranging from $628.76 to $628.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $627.22 | $3,763.32 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,393 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on January 3, 2022 at prices ranging from $627.00 to $627.31. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $626.48 | $3,132.40 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,399 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on January 3, 2022 at prices ranging from $626.29 to $626.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 45 | $625.56 | $28,150.20 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,404 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 45 shares of Company stock on January 3, 2022 at prices ranging from $625.00 to $625.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $624.30 | $8,740.20 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,449 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on January 3, 2022 at prices ranging from $624.04 to $624.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $623.62 | $11,848.78 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,463 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 19 shares of Company stock on January 3, 2022 at prices ranging from $623.41 to $623.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $622.52 | $4,980.16 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,482 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on January 3, 2022 at prices ranging from $622.32 to $622.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:22 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $621.98 | $621.98 |
DisclosureSEC source: 0001708138-22-000008 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,490 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $641.23 | $3,847.38 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,491 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on December 1, 2021 at prices ranging from $641.01 to $641.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $640.47 | $3,202.35 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,497 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on December 1, 2021 at prices ranging from $640.01 to $640.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 24 | $639.49 | $15,347.76 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,502 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 24 shares of Company stock on December 1, 2021 at prices ranging from $639.01 to $639.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $638.62 | $7,663.44 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,526 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on December 1, 2021 at prices ranging from $638.03 to $638.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 22 | $637.75 | $14,030.50 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,538 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 22 shares of Company stock on December 1, 2021 at prices ranging from $637.17 to $637.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $636.50 | $636.50 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,560 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $635.36 | $5,718.24 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,561 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on December 1, 2021 at prices ranging from $635.06 to $635.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $634.56 | $6,980.16 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,570 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on December 1, 2021 at prices ranging from $634.05 to $634.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $633.47 | $1,266.94 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,581 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on December 1, 2021 at prices ranging from $633.21 to $633.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $632.63 | $4,428.41 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,583 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on December 1, 2021 at prices ranging from $632.00 to $632.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2021 at each separate price. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $631.15 | $631.15 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,590 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 16, 2021 Filed Dec 2, 2021 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-21-000016 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,591 Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $647.00 | $5,176.00 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,091 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $646.37 | $3,231.85 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,099 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on November 1, 2021 at prices ranging from $646.00 to $646.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $645.41 | $9,681.15 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,104 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 15 shares of Company stock on November 1, 2021 at prices ranging from $645.01 to $645.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $644.62 | $5,801.58 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,119 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on November 1, 2021 at prices ranging from $644.21 to $644.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $643.82 | $643.82 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,128 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $642.28 | $5,780.52 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,129 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on November 1, 2021 at prices ranging from $642.00 to $642.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $641.52 | $12,188.88 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,138 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 19 shares of Company stock on November 1, 2021 at prices ranging from $641.11 to $641.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17 | $640.08 | $10,881.36 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,157 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 17 shares of Company stock on November 1, 2021 at prices ranging from $640.00 to $640.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 11 | $639.52 | $7,034.72 |
DisclosureSEC source: 0001883850-21-000007 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,174 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 11 shares of Company stock on November 1, 2021 at prices ranging from $639.17 to $639.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 1, 2021 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.